Benzinga - Gainers
- Clearmind Medicine Inc. (NASDAQ: CMND) gained 61.5% to $0.88 in pre-market trading after dropping around 3% on Tuesday. Clearmind engaged a contract research organization for its upcoming first-in-human study of MEAI compound while also filing an additional provisional patent application with partner SciSparc.
- SAI.TECH Global Corporation (NASDAQ: SAI) shares climbed 25.1% to $3.49 in pre-market trading after gaining 9% on Tuesday. SAI.TECH Global recently anounced appointments of Harry Sun to be Chief Technology Officer and Tao Wu to be Chief Operating Officer of SAI.TECH's new Product Line ULTIAAS.
- IN8bio, Inc. (NASDAQ: INAB) gained 20.4% to $2.30 in pre-market trading after dropping around 36% on Tuesday. IN8bio recently received FDA Orphan Drug Designation for INB-400/410 for the treatment of newly diagnosed glioblastoma.
- PacWest Bancorp (NASDAQ: PACW) surged 17.3% to $12.09 in pre-market trading after the company reported strong Q1 results and announced an increase in total deposits. The company also announced it took steps to maximize liquidity, including exploration of an asset sale.
- ETAO International Co., Ltd. (NASDAQ: ETAO) gained 13.6% to $0.8510 in pre-market trading after dropping more than 16% on Tuesday.
- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) jumped 11.8% to $0.2796 in pre-market trading after declining around 5% on Tuesday. Sonnet BioTherapeutics recently announced updated clinical data for SON-1010 at the 2023 American Association for Cancer Research Annual Meeting.
- Fisker Inc. (NYSE: FSR) gained 9.6% to $5.37 in pre-market trading after the company said European regulators have certified the Fisker Ocean SUV.
- CleanSpark, Inc. (NASDAQ: CLSK) climbed 9.3% to $4.01 in pre-market trading. CleanSpark recently announced the purchase of 45,000 units of the Antminer S19 XP bitcoin mining machines.
- The RealReal, Inc. (NASDAQ: REAL) climbed 8.4% to $1.16 in pre-market trading after dropping around 6% on Tuesday.
- Microsoft Corporation (NASDAQ: MSFT) gained 7.7% to $296.50 in pre-market trading as the company reported better-than-expected results for its third quarter on Tuesday.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Losers- Bed Bath & Beyond Inc. (NASDAQ: BBBY) fell 23.3% to $0.1523 in pre-market trading after the company received a delisting notice from the Nasdaq. Additionally, the company announced that it would cancel the Special Meeting of Shareholders that was scheduled for May 9.
- ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) fell 19.3% to $1.30 in pre-market trading after dropping over 5% on Tuesday. ZyVersa Therapeutics highlighted Publication In Article in Journal of Neuroinflammation on role of ASC specks in propagation of alpha-synuclein pathology in Parkinson's Disease.
- Enphase Energy, Inc. (NASDAQ: ENPH) fell 15.8% to $185.81 in pre-market after the company reported worse-than-expected Q1 sales and issued weak Q2 guidance.
- Lottery.com Inc. (NASDAQ: LTRY) shares dropped 15.3% to $0.4020 in pre-market trading after gaining around 32% on Tuesday. Lottery.com recently said it recommenced ticket operations.
- Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) fell 14.5% to $0.0726 in pre-market trading after jumping more than 25% on Tuesday.
- Apollomics, Inc. (NASDAQ: APLM) fell 12.7% to $5.63 in pre-market trading. Apollomics shares jumped around 60% on Tuesday after EF Hutton initiated coverage on the stock with a Buy rating and a $25 price target.
- IMV Inc. (NASDAQ: IMV) shares fell 11% to $0.7211 in pre-market trading after dropping 11% on Tuesday. IMV recently received Nasdaq notification regarding minimum bid price deficiency.
- Millennium Group International Holdings Limited (NASDAQ: MGIH) fell 10.3% to $1.75 in pre-market trading after gaining 10% on Tuesday.
- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell 9.8% to $0.33 in pre-market trading after gaining around 10% on Tuesday. TransCode Therapeutics recently announced equity investment of approximately $1.08m from White Lion capital to help fund development of TTX-MC138 for treatment of glioblastomas.
- Cyclo Therapeutics, Inc. (NASDAQ: CYTH) fell 7.6% to $0.8410 in pre-market trading after gaining around 14% on Tuesday.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Now Read This: Investor Sentiment Declines Further Amid Revived Concerns Over Banks
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.